Analysis of the response and toxicity to gefitinib of non-small cell lung cancer

Konishi, Jun; Yamazaki, Koichi; Kinoshita, Ichiro et al.

Anticancer Research, 2005, 25(1B), 435-441

Permalink : https://hdl.handle.net/2115/15889

このアイテムのアクセス数:1,696件（2026-04-15 07:37 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
AR25-1B pdf 252 KB 1,341

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/15889
タイトル
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
著者
Konishi, Jun ; Yamazaki, Koichi ; Kinoshita, Ichiro ; Isobe, Hiroshi ; Ogura, Shigeaki ; Sekine, Satoko ; Ishida, Takashi ; Takashima, Rioh ; Nakadate, Megumi ; Nishikawa, Syu ; Hattori, Takeshi ; Asahina, Hajime ; Imura, Mikado ; Kikuchi, Eiki ; Kikuchi, Junko ; Shinagawa, Naofumi ; Yokouchi, Hiroshi ; Munakata, Mituru ; Dosaka-Akita, Hirotoshi ; Nishimura, Masaharu
著者名
Konishi, Jun
著者名
Yamazaki, Koichi
著者名
Kinoshita, Ichiro
著者名
Isobe, Hiroshi
著者名
Ogura, Shigeaki
著者名
Sekine, Satoko
著者名
Ishida, Takashi
著者名
Takashima, Rioh
著者名
Nakadate, Megumi
著者名
Nishikawa, Syu
著者名
Hattori, Takeshi
著者名
Asahina, Hajime
著者名
Imura, Mikado
著者名
Kikuchi, Eiki
著者名
Kikuchi, Junko
著者名
Shinagawa, Naofumi
著者名
Yokouchi, Hiroshi
著者名
Munakata, Mituru
著者名
Dosaka-Akita, Hirotoshi
著者名
Nishimura, Masaharu
言語
英語
キーワード
Response
Toxicity
Non-small cell lung cancer
Gefitinib
発行日
2005
出版者
International Institute of Anticancer Research
収録物名
Anticancer Research
巻(号)
25(1B)
ページ
435-441
抄録
Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicitiy, and overall survival time of gefitinib in patients with NSCLC. Patients and Methods: One hundred and twenty-two patients with NSCLC who received gefitinib between 2002 and 2004 in our institutes were evaluated retrospectively. Results: The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included good performance status (PS), female, adenocarcinoma and never smoked status, and never smoked status and good PS were independent prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib. Conclusion: Gefitinib showed favorable anti-tumor activity in females, never smokers and adenocarcinoma.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
PISSN
0250-7005
関連情報
PMID
15816608